Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice
ConclusionsLow-dose mirabegron (25 mg) improves clinical outcomes in two-thirds of OAB patients with good safety profile and high persistence in daily urological practice. The therapeutic effect is similar between the genders.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
More News: Clinical Trials | Incontinence | Overactive Bladder | Overactive Bladder Syndrome | Statistics | Study | Urology & Nephrology